Korea alopecia areata JAK inhibitor cost and coverage guide
This guide explains drug-cost planning and the South Korea National Health Insurance reimbursement checklist for oral JAK inhibitors used in severe alopecia areata.
It covers Olumiant 4 mg and 2 mg tablets containing baricitinib, plus Litfulo 50 mg capsules containing ritlecitinib.
The Korean calculator separates MFDS marketing authorization from HIRA reimbursement because an approved prescription can still be billed at 100% self-pay.
Korea-specific information verified July 19, 2026.
The Olumiant prices come from the HIRA reimbursed-drug and ceiling-price list effective July 1, 2026, and the eligibility checklist follows HIRA Notice No. 2026-133 effective on the same date.
This is educational budget planning, not a diagnosis, SALT assessment, prescription, safety review, hospital quote, or HIRA coverage decision.
The result intentionally includes only the selected medicine.
Consultation, dispensing, laboratory monitoring, tuberculosis or hepatitis screening, treatment of adverse effects, travel, and unrelated services are outside the drug-only estimate.
Use the result as a list of questions for a dermatology visit and use the actual prescription and bill as the final figures.
What severe alopecia areata means
Alopecia areata is an immune-mediated disease in which inflammatory signaling disrupts the normal hair-growth cycle.
It may begin as one or more sharply outlined scalp patches, but severe disease can involve much of the scalp, the entire scalp, body hair, eyebrows, and eyelashes.
Its course is unpredictable, and visible regrowth or loss can change over time even without a straight-line relationship to cost.
Janus kinase inhibitors, usually shortened to JAK inhibitors, interrupt intracellular signals used by several inflammatory pathways.
Olumiant and Litfulo are oral medicines with different molecular targets, labeling details, precautions, and reimbursement status.
They do not guarantee permanent regrowth, and stopping treatment after a response may be followed by relapse, so the prescriber must balance continuing benefit against individual risk.
Scalp severity
HIRA uses the Severity of Alopecia Tool, or SALT, as an objective scalp-hair-loss measure.
The score ranges from 0, meaning no scalp hair loss, to 100, meaning complete scalp hair loss.
Facial-hair severity
Eyebrow and eyelash loss is not directly included in the scalp SALT number.
HIRA therefore provides a separate route for people with a baseline SALT from 20 to below 50 who also have qualifying bilateral eyebrow and eyelash loss.
How SALT thresholds work in this calculator
The calculator does not estimate SALT from a selfie.
Enter the score documented by the treating clinician because photographs, scalp-area weighting, and assessor technique can change a self-estimated number.
HIRA also requires objective material such as clinical photographs and the basis used to calculate the score.
Standard severity route
A baseline SALT 50 or higher satisfies the severity part of the initial checklist without the separate eyebrow-and-eyelash condition.
The exact boundary is inclusive, so 50 qualifies while 49.9 does not qualify through this route.
Special facial-hair route
A baseline score from 20 through 49.9 can satisfy the severity part only when both eyebrows and eyelashes are absent or clearly interrupted as specified by the verified criterion.
A value below 20 does not qualify through this route even if facial-hair loss is extensive.
Continuation threshold
The first continuation assessment occurs at week 36 and requires SALT 20 or lower.
An entered score of exactly 20 passes the numeric check, while 20.1 does not.
Official July 2026 prices and daily regimens
The HIRA list effective July 1, 2026 sets the ceiling price at KRW 18,942 per Olumiant 4 mg tablet and KRW 12,628 per Olumiant 2 mg tablet.
The calculator uses one tablet per day for either Olumiant strength and one capsule per day for Litfulo.
A selected number of months is converted to days with months multiplied by 365 and divided by 12, then rounded to a whole unit.
Comparison of Korean JAK inhibitor authorization, reimbursement status, dosing, and July 2026 unit prices| Product | Calculator regimen | Unit price | July 2026 status |
|---|
| Olumiant 4 mg | Baricitinib, one tablet daily | KRW 18,942 | Reimbursable for adults when every HIRA criterion is documented |
| Olumiant 2 mg | Baricitinib, one tablet daily | KRW 12,628 | Reimbursable for adults when every HIRA criterion is documented |
| Litfulo 50 mg | Ritlecitinib, one capsule daily | Enter actual quote | MFDS-authorized, but not found in the July 1 reimbursement list |
Litfulo deliberately starts at zero rather than an invented non-covered average.
Ask the provider or pharmacy for the actual package price and capsule count, divide the package price by the number of capsules, and enter that per-capsule amount.
Until a positive unit price is entered, the result shows that price input is required instead of presenting a zero-cost treatment.
MFDS authorization is not HIRA reimbursement
Both Olumiant and Litfulo are authorized in Korea for severe alopecia areata from age 12.
Under the current Olumiant label, an adolescent from age 12 through 17 must weigh at least 30 kg for the listed 4 mg daily regimen, and a reduction to 2 mg may be considered after sustained control.
Litfulo is labeled as 50 mg once daily from age 12 without the same calculator weight gate.
The verified HIRA baricitinib criterion addressed here applies to adults age 18 or older.
Therefore, the Korean result displays authorization and reimbursement checks separately.
A 16-year-old who meets an authorized age-and-weight profile does not become an adult reimbursement case merely because the medicine can legally be prescribed.
Dose selection remains clinical
The adult Olumiant recommended dose is 4 mg once daily, but the label recommends 2 mg for specified higher-risk patients, including people age 65 or older and those with higher risks involving venous thromboembolism, major adverse cardiovascular events, malignancy, or chronic or recurrent infection.
A clinician may consider 4 mg when response to 2 mg is inadequate and may consider reducing to 2 mg after sustained control.
The calculator compares prices but never recommends a strength, dose change, taper, or discontinuation.
Initial HIRA reimbursement checklist
HIRA Notice No. 2026-133 introduced the verified adult severe-alopecia-areata details effective July 1, 2026.
The calculator marks the initial check as satisfied only when the selected product is Olumiant and every numeric branch below is satisfied.
The display cannot verify whether the chart evidence is complete or whether HIRA will accept a claim.
- Adult age.
The patient must be age 18 or older for this reimbursement route.
- Prior conventional systemic treatment.
Treatment such as systemic corticosteroids or cyclosporine must have continued for at least three months with a SALT reduction below 30%, or the chart must document that treatment could not continue because of an adverse event or comparable reason.
- Baseline severity.
Baseline SALT must be 50 or higher, or it must be at least 20 and below 50 together with qualifying bilateral eyebrow and eyelash loss or clear interruption.
- Objective evidence.
Medication history, clinical photographs, and the documented basis for SALT calculation must support the request even though the calculator has no upload field.
Why exactly 30% matters
The implemented branch uses a reduction strictly below 30%.
A 29.9% reduction can satisfy the inadequate-response part after at least three months, while exactly 30% does not satisfy that branch.
Documented inability to continue because of adverse effects remains a separate alternative, so it can satisfy the prior-treatment branch without forcing the duration or response entries to look successful.
Continuation reviews and the two-year cap
The first response review occurs after 36 weeks of treatment and requires a current SALT of 20 or lower.
After that first review, the result must be maintained and documented every six months.
The reimbursed treatment period is capped at 24 months, so the Korean input will not accept a longer coverage-planning window.
Week 36First continuation assessment
Every 6 monthsLater maintenance assessment
Maximum 24 monthsReimbursed treatment window
The criterion also addresses prescription duration.
A prescription is generally limited to 30 days, but 60-to-90-day prescribing may be permitted after at least 24 weeks of stable treatment without adverse effects.
That rule affects how many tablets are dispensed at one visit, while this calculator estimates the total units needed over the selected planning period.
Do not stop a JAK inhibitor solely because a self-entered score crosses a calculator boundary.
Confirm the assessment date, scoring record, safety findings, and next treatment plan with the prescriber.
Cost formulas and worked examples
Drug-only formulas
Required units = round(treatment months × 365 ÷ 12)
List drug cost = unit price × required units
Covered estimate = round(list drug cost × 30%)
Non-covered estimate = list drug cost × 100%
Average monthly budget = patient drug cost ÷ treatment months
Olumiant 4 mg for 12 months
- Required tablets: 365.
- Full list cost: 18,942 × 365 = KRW 6,913,830.
- Covered 30% drug copay: KRW 2,074,149.
- Estimated NHI share: KRW 4,839,681.
Olumiant 2 mg for 12 months
- Required tablets: 365.
- Full list cost: 12,628 × 365 = KRW 4,609,220.
- Covered 30% drug copay: KRW 1,382,766.
- Estimated NHI share: KRW 3,226,454.
One month produces 30 units because 365 divided by 12 is rounded to the nearest whole tablet or capsule.
Twelve months produces 365 units, and 24 months produces 730 units.
Real prescriptions use actual calendar days and pack sizes, so a pharmacy invoice can differ from the average-month conversion.
If an Olumiant eligibility condition fails, the calculator applies 100% of the entered drug price rather than the 30% covered estimate.
Litfulo also remains a 100% self-pay scenario under the verified July 2026 list, even if the entered age satisfies its MFDS authorization.
The comparison table applies the same clinical entries to both Olumiant strengths but never implies that the less expensive strength is medically interchangeable.
How to use the Korean calculator correctly
1Choose the prescribed or discussed medicine
Select Olumiant 4 mg, Olumiant 2 mg, or Litfulo 50 mg. Choosing a product resets the unit price to its official ceiling or to zero when no official reimbursed price is available.
2Choose initial or continuation review
Use the initial stage before covered treatment begins. Use continuation for the week-36 or later six-month review because that adds the current-SALT requirement.
3Copy documented values
Enter age, weight, prior systemic-treatment duration and response, baseline SALT, facial-hair status, and current SALT from clinical records rather than memory where possible.
4Set a planning period
Choose from 1 through 24 months. The result converts the period into daily units and shows list cost, expected patient drug cost, NHI share, and a monthly average.
Reading green and amber checks
A green row means only that the entered number satisfies the coded boundary.
An amber row identifies a failed number or a product that is not in the verified reimbursement route.
Neither color verifies diagnosis, medical necessity, complete evidence, contraindications, claim coding, or the final decision by the provider and HIRA.
Practical planning scenarios
Adult initial review with SALT above 50
A 35-year-old enters three months of prior systemic treatment, a 20% SALT reduction, and baseline SALT 60.
The numeric initial branches pass for Olumiant because age is at least 18, prior treatment lasted at least three months with reduction below 30%, and baseline SALT is at least 50.
The result still instructs the user to prepare the exact medication history, photographs, and SALT basis because those materials are not verified by the form.
Adult initial review with SALT below 50
Baseline SALT 35 fails the standard severity route.
It can pass the coded special route only when the user also confirms qualifying bilateral eyebrow and eyelash loss or clear interruption.
Checking that box without a clinician-documented finding can make the planning result misleading.
Adolescent authorization discussion
A 16-year-old weighing 45 kg can satisfy the calculator’s Olumiant label-age and adolescent-weight checks.
The adult reimbursement row still fails because the entered age is below 18.
This separation helps a family ask about a medically authorized prescription without assuming that the current adult NHI route will pay for it.
Litfulo budget discussion
Selecting Litfulo clears the price because no HIRA ceiling is used for this scenario.
After a user enters a real per-capsule quote, the calculator multiplies it by the daily unit count and treats the total as self-pay.
If future reimbursement is introduced, the official list, code, price, criteria, tests, and both language guides must be updated together before the result changes.
Records to prepare for a dermatology visit
A cost estimate becomes more useful when it is paired with a complete treatment timeline.
Bring records that allow the clinician to distinguish a treatment that was ineffective from one that was stopped early, used at an inadequate dose, or ended because of a safety issue.
Ask the clinic which photographs and SALT worksheet are needed for the relevant review date.
- Names, doses, start dates, and end dates of systemic corticosteroids, cyclosporine, or other conventional systemic treatments.
- Documented adverse effects, contraindications, or another reason a prior systemic treatment could not continue.
- Baseline and follow-up SALT scores with the underlying scoring worksheet or chart entry.
- Clinical photographs taken under comparable lighting, angle, hair preparation, and scalp coverage conditions.
- Documentation of bilateral eyebrow and eyelash loss when using the SALT 20-to-below-50 branch.
- The week-36 assessment and every later six-month maintenance assessment when reimbursement continues.
- All current medicines, vaccination history, infection history, smoking history, and major cardiovascular or thrombotic risk information.
Safety and monitoring are not optional costs
JAK inhibitors carry important safety warnings and require an individualized benefit-risk decision.
Screening commonly considers active or latent tuberculosis, serious or recurrent infection, viral hepatitis, blood counts, liver function, vaccination status, pregnancy, and interacting or overlapping immunosuppressive treatment.
The exact tests and schedule depend on the product, patient, and clinical findings.
Discuss before treatment
- Current fever, infection, untreated tuberculosis, or recent exposure.
- Past shingles, hepatitis, recurrent infection, or abnormal blood counts.
- Venous thromboembolism, cardiovascular disease, cancer, and smoking risk.
- Pregnancy plans, pregnancy, breastfeeding, and live-vaccine timing.
Report during treatment
- Fever, persistent cough, painful rash, or possible shingles.
- Chest pain, sudden shortness of breath, or unilateral leg swelling.
- Unexpected bruising, fatigue, jaundice, or laboratory abnormalities.
- Any instruction to pause, reduce, switch, or stop treatment.
Olumiant labeling advises considering discontinuation when there is no evidence of therapeutic benefit by 36 weeks.
That clinical judgment is related to, but not identical with, the HIRA continuation boundary.
Never use a favorable budget output to override a safety warning or continue a medicine against medical advice.
What the 30% estimate includes and excludes
National Health Insurance Act Article 44 provides for patient cost sharing, while Enforcement Decree Article 19 delegates detailed shares to Annex 2.
The Korean calculator uses the ordinary 30% pharmacy drug share as a simplified covered estimate.
It does not claim that every visit or hospital item is billed at that same percentage.
Covered patient payments may count toward Korea’s annual out-of-pocket ceiling, depending on the person’s income tier and all qualifying covered costs during the year.
Non-covered Litfulo spending and other excluded services generally do not become ceiling-eligible merely because they were medically recommended.
This calculator does not guess a ceiling refund because it has no household-income tier or whole-year claim history.
Private indemnity insurance and the medical-expense tax credit have separate contract and tax requirements.
Keep prescriptions, itemized receipts, payment records, diagnosis documentation, and insurer responses, and ask the insurer or tax professional about the actual plan year.
Do not subtract an expected private-insurance payment from the medicine price unless the insurer has confirmed coverage for that exact claim.
Common boundary mistakes
Treating 30% reduction as failure
The code uses less than 30%, not less than or equal to 30%, for the inadequate-response branch.
Enter the documented percentage with one decimal place when the value is near the boundary.
Ignoring the three-month duration
A low response after only two months does not satisfy the standard duration branch.
Documented inability to continue because of adverse effects is the separate alternative.
Using unilateral facial-hair loss
The special SALT route is not a generic checkbox for any eyebrow or eyelash change.
Use it only when the documented bilateral finding matches the criterion.
Equating approval with payment
Age-12 authorization does not remove the age-18 adult reimbursement boundary.
Likewise, an authorized Litfulo prescription does not create a HIRA ceiling price that was absent from the verified list.
Frequently asked questions
Does baseline SALT below 50 always fail reimbursement?
No.
Baseline SALT from 20 to below 50 can satisfy the severity branch when the qualifying bilateral eyebrow and eyelash finding is also documented.
Baseline below 20 does not satisfy that branch.
Is Olumiant covered for a 12-year-old because it is authorized from age 12?
Not through the adult criterion implemented here.
The product authorization and adolescent weight rule must be separated from HIRA’s verified age-18 reimbursement route.
Ask the provider for the current claim status and expected self-pay before treatment.
Should I choose 2 mg because it costs less?
No cost calculator can select a safe and effective Olumiant strength.
The clinician considers response, age, infection history, venous-thromboembolism risk, cardiovascular risk, malignancy risk, kidney function, other medicines, and whether treatment is being tapered after sustained control.
Why does Litfulo have no default price?
Litfulo was not found in the HIRA reimbursement list effective July 1, 2026.
Non-covered prices are provider-set and can change, so the calculator requires an actual per-capsule quote instead of publishing an unsupported average.
Does current SALT 20 guarantee continuation approval?
No.
It passes the numeric continuation boundary, but the initial criteria, correct assessment timing, objective documentation, safety review, and actual HIRA claim decision still matter.
Is the maximum covered period one year?
The verified baricitinib alopecia-areata criterion allows a maximum of two years, represented as 24 months in the calculator.
Continued eligibility is not automatic during that window because the week-36 and later six-month assessments must be satisfied.
Why can the actual bill differ from 30% of the list price?
The displayed percentage is a simplified ordinary pharmacy drug-share estimate.
Actual calendar days, pack size, dispensing, consultation, laboratory services, claim rounding, provider setting, special rules, and unrelated services can change the invoice.
Can I use this result to start or stop treatment?
No.
Starting, changing, reducing, pausing, or stopping a JAK inhibitor requires the prescriber’s assessment of response and safety.
Seek urgent medical advice for serious infection symptoms, chest pain, sudden breathing difficulty, or one-sided leg swelling.
Official sources and update triggers
- HIRA Notice No. 2026-133 and its attached revision for oral baricitinib, posted June 25, 2026 and effective July 1, 2026.
- HIRA List of Reimbursed Drugs and Ceiling Prices effective July 1, 2026, including product codes 670801130 for Olumiant 4 mg and 670801120 for Olumiant 2 mg.
- MFDS NEDrug product information for Olumiant 2 mg, item sequence 201708280, and Olumiant 4 mg, item sequence 201708281.
- MFDS authorization material for Litfulo 50 mg and the current Korean product information for ritlecitinib.
- National Health Insurance Act Articles 41 and 44, Enforcement Decree Article 19 and Annex 2, and the Rule on Standards for National Health Insurance Medical Benefits Article 5.
Recheck the calculator when an Olumiant ceiling price changes, Litfulo enters the reimbursement list, another alopecia-areata JAK inhibitor is authorized or reimbursed, or HIRA changes age, prior-treatment, SALT, facial-hair, review, prescription-duration, or maximum-period rules.
Label changes involving dose, adolescent weight, monitoring, contraindications, or the 36-week benefit assessment also require synchronized updates to data, logic, tests, and both language guides.
Recalculate with documented values, then confirm the treatment plan
Enter the actual medicine, prior systemic-treatment history, clinician-recorded SALT values, and planning period.
Take the cost comparison and unmet checklist to the dermatology consultation; the treating team, provider invoice, and latest HIRA rule remain authoritative.